PubMed:17261671 / 763-1079 JSONTXT

{"project":"PubMed_ArguminSci","denotations":[{"id":"T4","span":{"begin":0,"end":316},"obj":"DRI_Approach"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"Inflammaging","denotations":[{"id":"T5","span":{"begin":0,"end":316},"obj":"Sentence"},{"id":"T5","span":{"begin":0,"end":316},"obj":"Sentence"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":53,"end":62},"obj":"gene:5465"},{"id":"T1","span":{"begin":300,"end":315},"obj":"disease:C0003850"},{"id":"T2","span":{"begin":53,"end":62},"obj":"gene:5465"},{"id":"T3","span":{"begin":300,"end":315},"obj":"disease:C0004153"},{"id":"T4","span":{"begin":103,"end":112},"obj":"gene:5468"},{"id":"T5","span":{"begin":300,"end":315},"obj":"disease:C0003850"},{"id":"T6","span":{"begin":103,"end":112},"obj":"gene:5468"},{"id":"T7","span":{"begin":300,"end":315},"obj":"disease:C0004153"},{"id":"T8","span":{"begin":257,"end":261},"obj":"gene:5465"},{"id":"T9","span":{"begin":300,"end":315},"obj":"disease:C0003850"},{"id":"T10","span":{"begin":257,"end":261},"obj":"gene:5465"},{"id":"T11","span":{"begin":300,"end":315},"obj":"disease:C0004153"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"},{"id":"R6","pred":"associated_with","subj":"T10","obj":"T11"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":300,"end":315},"obj":"HP_0002621"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"17261671-4#53#62#gene5465","span":{"begin":53,"end":62},"obj":"gene5465"},{"id":"17261671-4#103#112#gene5468","span":{"begin":103,"end":112},"obj":"gene5468"},{"id":"17261671-4#300#315#diseaseC0003850","span":{"begin":300,"end":315},"obj":"diseaseC0003850"},{"id":"17261671-4#300#315#diseaseC0004153","span":{"begin":300,"end":315},"obj":"diseaseC0004153"},{"id":"17261671-4#300#315#diseaseC0003850","span":{"begin":300,"end":315},"obj":"diseaseC0003850"},{"id":"17261671-4#300#315#diseaseC0004153","span":{"begin":300,"end":315},"obj":"diseaseC0004153"}],"relations":[{"id":"53#62#gene5465300#315#diseaseC0003850","pred":"associated_with","subj":"17261671-4#53#62#gene5465","obj":"17261671-4#300#315#diseaseC0003850"},{"id":"53#62#gene5465300#315#diseaseC0004153","pred":"associated_with","subj":"17261671-4#53#62#gene5465","obj":"17261671-4#300#315#diseaseC0004153"},{"id":"53#62#gene5465300#315#diseaseC0003850","pred":"associated_with","subj":"17261671-4#53#62#gene5465","obj":"17261671-4#300#315#diseaseC0003850"},{"id":"53#62#gene5465300#315#diseaseC0004153","pred":"associated_with","subj":"17261671-4#53#62#gene5465","obj":"17261671-4#300#315#diseaseC0004153"},{"id":"103#112#gene5468300#315#diseaseC0003850","pred":"associated_with","subj":"17261671-4#103#112#gene5468","obj":"17261671-4#300#315#diseaseC0003850"},{"id":"103#112#gene5468300#315#diseaseC0004153","pred":"associated_with","subj":"17261671-4#103#112#gene5468","obj":"17261671-4#300#315#diseaseC0004153"},{"id":"103#112#gene5468300#315#diseaseC0003850","pred":"associated_with","subj":"17261671-4#103#112#gene5468","obj":"17261671-4#300#315#diseaseC0003850"},{"id":"103#112#gene5468300#315#diseaseC0004153","pred":"associated_with","subj":"17261671-4#103#112#gene5468","obj":"17261671-4#300#315#diseaseC0004153"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T1817","span":{"begin":53,"end":62},"obj":"gene:5465"},{"id":"T1818","span":{"begin":300,"end":315},"obj":"disease:C0003850"},{"id":"T1819","span":{"begin":103,"end":112},"obj":"gene:5468"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T1817","obj":"T1818"},{"id":"R2","pred":"associated_with","subj":"T1817","obj":"T1818"},{"id":"R3","pred":"associated_with","subj":"T1819","obj":"T1818"},{"id":"R4","pred":"associated_with","subj":"T1819","obj":"T1818"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T5","span":{"begin":0,"end":316},"obj":"Sentence"},{"id":"T5","span":{"begin":0,"end":316},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis."}